Cargando…

Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers

BACKGROUND: Non-adherence to secondary prevention medicines (SPMs) among patients with coronary artery disease (CAD) remains a challenge in clinical practice. This study attempted to identify actual and potential modifiable barriers to adherence that can be addressed in cardiology clinical practice....

Descripción completa

Detalles Bibliográficos
Autores principales: Khatib, Rani, Marshall, Kay, Silcock, Jon, Forrest, Claire, Hall, Alistair S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615814/
https://www.ncbi.nlm.nih.gov/pubmed/31354954
http://dx.doi.org/10.1136/openhrt-2018-000997
_version_ 1783433405146333184
author Khatib, Rani
Marshall, Kay
Silcock, Jon
Forrest, Claire
Hall, Alistair S
author_facet Khatib, Rani
Marshall, Kay
Silcock, Jon
Forrest, Claire
Hall, Alistair S
author_sort Khatib, Rani
collection PubMed
description BACKGROUND: Non-adherence to secondary prevention medicines (SPMs) among patients with coronary artery disease (CAD) remains a challenge in clinical practice. This study attempted to identify actual and potential modifiable barriers to adherence that can be addressed in cardiology clinical practice. METHODS: This was a cross-sectional, postal survey-based study of the medicines-taking experience of patients with CAD treated at a secondary/tertiary care centre. All participants had been on SPM for ≥3 months. RESULTS: In total, 696 eligible patients were sent the survey and 503 responded (72.3%). The median age was 70 years, and 403 (80.1%) were male; the median number of individual daily doses of all medicines was 6. The rate of non-adherence to at least one SPM was 43.5% (n=219), but 53.3% of reported non-adherence was to only one SPM. Statins contributed to 66.7% and aspirin to 61.7% of overall non-adherence identified by the Single Question (SQ) tool. In 30.8% of non-adherent patients (n=65), this was at least partly intentional. Barriers included forgetfulness (84.9%; n=186), worry that medicines will do more harm than good (33.8%; n=74), feeling hassled about medicines taking (18.7%; n=41), feeling worse when taking medicines (14.2%; n=31) and not being convinced of the benefit of medicines (9.1%; n=20). In a multivariate analysis, modifiable factors associated with overall non-adherence included being prescribed aspirin (OR: 2.22; 95% CI: 1.18 to 4.17), having specific concern about SPM (OR: 1.12; 95% CI: 1.07 to 1.18) and issues with repeat prescriptions (OR: 2.48; 95% CI: 1.26 to 4.90). Different factors were often associated with intentional versus unintentional non-adherence. CONCLUSIONS: Using appropriate self-report tools, patients share actual and potential modifiable barriers to adherence that can be addressed in clinical practice. Non-adherence behaviour was selective. Most non-adherence was driven by forgetfulness, concern about the harm caused by SPM and practical barriers.
format Online
Article
Text
id pubmed-6615814
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-66158142019-07-28 Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers Khatib, Rani Marshall, Kay Silcock, Jon Forrest, Claire Hall, Alistair S Open Heart Coronary Artery Disease BACKGROUND: Non-adherence to secondary prevention medicines (SPMs) among patients with coronary artery disease (CAD) remains a challenge in clinical practice. This study attempted to identify actual and potential modifiable barriers to adherence that can be addressed in cardiology clinical practice. METHODS: This was a cross-sectional, postal survey-based study of the medicines-taking experience of patients with CAD treated at a secondary/tertiary care centre. All participants had been on SPM for ≥3 months. RESULTS: In total, 696 eligible patients were sent the survey and 503 responded (72.3%). The median age was 70 years, and 403 (80.1%) were male; the median number of individual daily doses of all medicines was 6. The rate of non-adherence to at least one SPM was 43.5% (n=219), but 53.3% of reported non-adherence was to only one SPM. Statins contributed to 66.7% and aspirin to 61.7% of overall non-adherence identified by the Single Question (SQ) tool. In 30.8% of non-adherent patients (n=65), this was at least partly intentional. Barriers included forgetfulness (84.9%; n=186), worry that medicines will do more harm than good (33.8%; n=74), feeling hassled about medicines taking (18.7%; n=41), feeling worse when taking medicines (14.2%; n=31) and not being convinced of the benefit of medicines (9.1%; n=20). In a multivariate analysis, modifiable factors associated with overall non-adherence included being prescribed aspirin (OR: 2.22; 95% CI: 1.18 to 4.17), having specific concern about SPM (OR: 1.12; 95% CI: 1.07 to 1.18) and issues with repeat prescriptions (OR: 2.48; 95% CI: 1.26 to 4.90). Different factors were often associated with intentional versus unintentional non-adherence. CONCLUSIONS: Using appropriate self-report tools, patients share actual and potential modifiable barriers to adherence that can be addressed in clinical practice. Non-adherence behaviour was selective. Most non-adherence was driven by forgetfulness, concern about the harm caused by SPM and practical barriers. BMJ Publishing Group 2019-07-03 /pmc/articles/PMC6615814/ /pubmed/31354954 http://dx.doi.org/10.1136/openhrt-2018-000997 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Coronary Artery Disease
Khatib, Rani
Marshall, Kay
Silcock, Jon
Forrest, Claire
Hall, Alistair S
Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
title Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
title_full Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
title_fullStr Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
title_full_unstemmed Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
title_short Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
title_sort adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers
topic Coronary Artery Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615814/
https://www.ncbi.nlm.nih.gov/pubmed/31354954
http://dx.doi.org/10.1136/openhrt-2018-000997
work_keys_str_mv AT khatibrani adherencetocoronaryarterydiseasesecondarypreventionmedicinesexploringmodifiablebarriers
AT marshallkay adherencetocoronaryarterydiseasesecondarypreventionmedicinesexploringmodifiablebarriers
AT silcockjon adherencetocoronaryarterydiseasesecondarypreventionmedicinesexploringmodifiablebarriers
AT forrestclaire adherencetocoronaryarterydiseasesecondarypreventionmedicinesexploringmodifiablebarriers
AT hallalistairs adherencetocoronaryarterydiseasesecondarypreventionmedicinesexploringmodifiablebarriers